Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry
Study to study 52-week effectiveness and safety of dupilumab in adult patients with treatment-refractory atopic dermatitis. Results showed a greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16.
